...
首页> 外文期刊>Resuscitation. >Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation
【24h】

Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation

机译:胺碘酮和利多卡因在无脉冲室性心动过速或心室纤颤治疗医院内小儿心脏骤停中的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: To determine the association between amiodarone and lidocaine and outcomes in children with cardiac arrest with pulseless ventricular tachycardia (pVT) and ventricular fibrillation (VF). Background: Current AHA guidelines for CPR and emergency cardiovascular care recommend amiodarone for cardiac arrest in children associated with shock refractory pVT/VF, based on a single pediatric study and extrapolation from adult data. Methods: Retrospective cohort study from the Get With the Guidelines-Resuscitation database for in-patient cardiac arrest. Patients. < 18 years old with pVT/VF cardiac arrest were included. Patients receiving amiodarone or lidocaine prior to arrest or whose initial arrest rhythm was unknown were excluded. Univariate analysis was performed to assess the association between patient and event factors and clinical outcomes. Multivariate analysis was performed to address independent association between lidocaine and amiodarone use and outcomes. Results: Of 889 patients, 171 (19%) received amiodarone, 295 (33%) received lidocaine, and 82 (10%) received both. Return of spontaneous circulation (ROSC) occurred in 484/889 (54%), 24-h survival in 342/874 (39%), and survival to hospital discharge in 194/889 (22%). Lidocaine was associated with improved ROSC (adjusted OR 2.02, 95% CI 1.36-3), and 24-h survival (adjusted OR 1.66, 95% CI 1.11-2.49), but not hospital discharge. Amiodarone use was not associated with ROSC, 24. h survival, or survival to discharge. Conclusions: For children with in-hospital pVT/VF, lidocaine use was independently associated with improved ROSC and 24-h survival. Amiodarone use was not associated with superior rates of ROSC, survival at 24. h. Neither drug was associated with survival to hospital discharge.
机译:目的:确定胺碘酮和利多卡因与无心室性心动过速(pVT)和心室纤颤(VF)的心脏骤停患儿的预后之间的关系。背景:当前的美国心脏协会心肺复苏和心血管急救指南建议,胺碘酮可用于单次儿科研究并从成人数据中推断出的休克难治性pVT / VF相关儿童的心脏骤停。方法:从Get With the Guidelines-Resurcitation数据库获取的住院心脏骤停的回顾性队列研究。耐心。包括18岁以下的pVT / VF心脏骤停。逮捕之前接受胺碘酮或利多卡因治疗或最初的停止节奏未知的患者。进行单因素分析以评估患者和事件因素与临床结果之间的关联。进行多变量分析以解决利多卡因和胺碘酮使用与结局之间的独立关联。结果:在889例患者中,有171例(19%)接受了胺碘酮,295例(33%)接受了利多卡因,而82例(10%)都接受了胺碘酮。自发循环(ROSC)的恢复发生在484/889(54%),24小时生存率在342/874(39%),而出院生存率在194/889(22%)。利多卡因与改善的ROSC(校正后的OR 2.02,95%CI 1.36-3)和24小时生存率(校正后的OR 1.66,95%CI 1.11-2.49)相关,但与出院无关。胺碘酮的使用与ROSC,24小时生存率或出院生存率无关。结论:对于住院pVT / VF的儿童,利多卡因的使用与改善的ROSC和24小时生存率独立相关。胺碘酮的使用与较高的ROSC率,24小时生存率无关。两种药物均与出院生存率无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号